CXCL13

Across TCGA pan-cancer cohorts, CXCL13 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CXCL13 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CXCL13 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CXCL13 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

GBM, HNSC, and LUAD are the cancer types where CXCL13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.536	0.947	.001	35	view →
HNSC	OS	Tertile	All	1.000	0.277	.013	22	view →
LUAD	DFS	Quartile	All	0.866	0.634	.005	21	view →
LSCC	DFS	Quartile	II,III,IV	0.391	1.000	<.001	15	view →
PDAC	DFS	Tertile	II,III,IV	0.409	0.833	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CXCL13–GBM (DFS)

Open the GBM breakdown →